14 research outputs found
Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis
Both cannabis use and the dopamine receptor (DRD2) gene have been associated with schizophrenia, psychosis-like experiences, and cognition. However, there are no published data investigating whether genetically determined variation in DRD2 dopaminergic signaling might play a role in individual susceptibility to cannabis-associated psychosis. We genotyped (1) a case-control study of 272 patients with their first episode of psychosis and 234 controls, and also from (2) a sample of 252 healthy subjects, for functional variation in DRD2, rs1076560. Data on history of cannabis use were collected on all the studied subjects by administering the Cannabis Experience Questionnaire. In the healthy subjects' sample, we also collected data on schizotypy and cognitive performance using the Schizotypal Personality Questionnaire and the N-back working memory task. In the case-control study, we found a significant interaction between the rs1076560 DRD2 genotype and cannabis use in influencing the likelihood of a psychotic disorder. Among cannabis users, carriers of the DRD2, rs1076560, T allele showed a 3-fold increased probability to suffer a psychotic disorder compared with GG carriers (OR = 3.07; 95% confidence interval [CI]: 1.22-7.63). Among daily users, T carrying subjects showed a 5-fold increase in the odds of psychosis compared to GG carriers (OR = 4.82; 95% CI: 1.39-16.71). Among the healthy subjects, T carrying cannabis users had increased schizotypy compared with T carrying cannabis-naïve subjects, GG cannabis users, and GG cannabis-naïve subjects (all P ≤ .025). T carrying cannabis users had reduced working memory accuracy compared with the other groups (all P ≤ .008). Thus, variation of the DRD2, rs1076560, genotype may modulate the psychosis-inducing effect of cannabis us
Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis
Both cannabis use and the dopamine receptor (DRD2) gene
have been associated with schizophrenia, psychosis-like
experiences, and cognition. However, there are no published
data investigating whether genetically determined variation
in DRD2 dopaminergic signaling might play a role in
individual susceptibility to cannabis-associated psychosis.
We genotyped (1) a case-control study of 272 patients with
their first episode of psychosis and 234 controls, and also
from (2) a sample of 252 healthy subjects, for functional
variation in DRD2, rs1076560. Data on history of cannabis
use were collected on all the studied subjects by administering
the Cannabis Experience Questionnaire. In the healthy
subjects’ sample, we also collected data on schizotypy and
cognitive performance using the Schizotypal Personality
Questionnaire and the N-back working memory task. In
the case-control study, we found a significant interaction
between the rs1076560 DRD2 genotype and cannabis use
in influencing the likelihood of a psychotic disorder. Among
cannabis users, carriers of the DRD2, rs1076560, T allele
showed a 3-fold increased probability to suffer a psychotic
disorder compared with GG carriers (OR = 3.07; 95%
confidence interval [CI]: 1.22–7.63). Among daily users, T
carrying subjects showed a 5-fold increase in the odds of
psychosis compared to GG carriers (OR = 4.82; 95% CI:
1.39–16.71). Among the healthy subjects, T carrying cannabis
users had increased schizotypy compared with T carrying
cannabis-naïve subjects, GG cannabis users, and GG
cannabis-naïve subjects (all P ≤ .025). T carrying cannabis
users had reduced working memory accuracy compared
with the other groups (all P ≤ .008). Thus, variation of the
DRD2, rs1076560, genotype may modulate the psychosisinducing
effect of cannabis use
Neurobehavioral traits in family members inform gene discovery in ASD
Outline: Autism Spectrum Disorder; Hetereogeneity of diagnosis and presence of comorbidities; Quantitative Autism Score (QAS) as continuous set outcome for analyses; Different patients and different family history for neurobehavioral disorders; Genetic analyses; ResultsN/
Identification of molecular alterations in neurotransmission and synaptic genes in Autism Spectrum Disorder
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder, which affects brain function. It is characterized by the presence of social communication deficits and restricted, repetitive patterns of behavior. ASD has a strong genetic component and there is evidence in support of many putative risk genes. However, the genetics and the biological processes underlying the disease are still incompletely understood and will require the integration of intermediate phenotypic analysis provided by direct observation tools such as brain imaging.Support for this work was provided by Fundação para a Ciência e a Tecnologia (Grant PD/BD/131390/2017 to Joana Vilela).info:eu-repo/semantics/draf